Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineDaniel D. Von Hoff, Markus F. Renschler, Mansoor N. Saleh et al.|New England Journal of Medicine|2013Cited by 6.6k
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 TrialWilliam Greenhalf, Markus W. Büchler, Paula Ghaneh et al.|JNCI Journal of the National Cancer Institute|2013Cited by 333
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumorsCharlotte Lemech, David Goldstein|Journal for ImmunoTherapy of Cancer|2023Cited by 38
Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myelomaDouglas Joshua, David Goldstein|British Journal of Haematology|1997Cited by 35
TLR4 downregulation protects against cisplatin-induced ototoxicity in adult and pediatric patients with cancerAmit P. Bhavsar, Asna Latif, Erika N. Scott et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 4